Career Development Bridge Funding Award: K Bridge

The mission of the Rheumatology Research Foundation is to advance research and training to improve the health of people with rheumatic diseases.

The purpose of this award is to provide bridge funding for promising investigators as they are revising outstanding individual career development award applications (i.e., applications for NIH K series awards, VA CDA-2 awards, or any equivalent career development awards). Through this bridge funding award, the Foundation will support young faculty members so that they have the highest likelihood of achieving success in obtaining longer term career development awards.

Award Amount: Up to \$75,000

Award Duration: 1 Year

All applications must be submitted by 5:00 pm ET on the deadline day through ProposalCentral.

If you have any questions about your eligibility or submitting your application, please contact Award & Grants staff at 404-365-1373 or Foundation@rheumatology.org.

Applications are accepted twice per year as detailed below:

	CYCLE I	CYCLE II
Application Opens	April 1, 2024	August 1, 2024
Application Deadline	June 3, 2024	October 1, 2024
Award Notification	July 1, 2024	November 1, 2024

Guidelines

All award recipients must abide by Foundation Awards and Grants Policies at all times.

Eligibility

Applicants must be <u>ACR</u> or <u>ARP</u> members with an MD, DO, PhD or equivalent doctoral level degree from an accredited institution.

ACR members must meet the following criteria:	ARP members must meet the following criteria:
must meet the following criteria.	must meet the following criteria.
 Applicants must have received a priority score and summary statement on their NIH K08, K23, K25, K99/R00, or VA CDA-2 award. Applicants whose career development applications were unscored are not eligible. Have earned a DO, MD, MD/PhD, or DO/PhD degree or be currently enrolled in an ACGME accredited clinical training program and have completed at least one year of training by the start of the award term. MDs or DOs who are not licensed to perform clinical care in the U.S. may not apply. 	 Applicants must have received a priority score, summary statement, and funding decision on their on their NIH K01, K08, K23, K25, K99/R00, or VA CDA-2 award. Applicants whose career development applications were unscored are not eligible. Have earned a PhD*, DSc, or equivalent doctoral degree

- > *The Foundation does not currently support non-MD/DO scientists working on basic science research.
- > Bridge funds are not intended to bridge the period between review and funding.
- Applications from individuals from groups underrepresented in medicine are particularly encouraged.
- Previous recipients of this award are not eligible to apply.
- In addition to an excellent application, applicants must be capable of becoming independent researchers with a clear and firm institutional commitment to their career development, including a faculty position and other supporting resources.

Review Criteria

All applications will undergo peer review and final funding decisions will be made by the Foundation Scientific Advisory Council. Applications will be reviewed on the following criteria:

Relevance of the proposal to the Foundation's mission to improve the health of people with rheumatic disease

- Experience and productivity as a rheumatology fellow and/or junior faculty member
- Having obtained a priority score and critique/summary statement from NIH/VA study section
- Strategy to address comments in the critique/summary statement
- Evidence of strong scientific and career mentoring
- > Demonstration of institutional support

Applicants will be notified of their status within one month of the application deadline.

Award Terms and Funding

The award term is a maximum of one year at up to \$75,000 in direct costs. The amount of the award can be divided between salary and fringe benefits and/or research costs (up to a maximum of \$25,000 research costs). The total salary requested must be based on a full-time, 12-month faculty appointment requiring the candidate to devote a minimum of 75% of full-time professional effort to conducting research with the remaining effort being devoted to activities related to the development of a successful research career. **The Foundation does not allow indirect costs to the institution through this mechanism.**

Payment will be made in two equal installments. The first payment will be released within 2 weeks of award notification pending receipt of contractual documents, and the second payment will be made six months thereafter.

The grant is not renewable. If an applicant receives NIH, FDA and CDC grant or another equivalent award during the bridge funding award term, the applicant must notify the Foundation and return the unused portion of the Foundation bridge funding award.

Recipients must notify the Foundation when they re-submit their application to the NIH or VA. Re-submission is expected during the bridge funding period. Recipients must demonstrate significant progress in generating preliminary data and revising their grant proposal in the first six months to receive additional funding.

ORCID provides a persistent digital identifier (an ORCID ID) that you own and control, and that distinguishes you from every other researcher. Applicants are required to connect their ORCID Identification Number with PropsalCentral at the time of application. If the applicant does not have an ORCID Identification Number, one should be created and connected to the application prior to submission. If selected for funding, applicant will be required to "Trust" the Rheumatology Research Foundation as an organization to optimize tracking of project metrics. For instructions on how to link your ORCID ID with your application in ProposalCentral, visit this link and scroll to page 35.

Application Instructions

Before starting the online application, you will be required to create a Professional Profile in ProposalCentral, if you have not already. To do so, visit this link to begin creating your account.

All files must be saved as a PDF. Documents that do not have a required template should be formatted with ½ inch margin, 11-point Arial Font, and single-spacing (does not apply to figures and tables). All applications and documents must be written in English and avoid use of jargon. If terms are not universally known, spell out the term the first time it is used and note the appropriate abbreviation in parentheses. The acronym may be used thereafter.

Note: The Foundation does not require an official signature from an authorized institutional research office at the time of application. However, many institutions require an application to be reviewed prior to submission. Please check with your research office for your institution's requirements.

Applicant/Principal Investigator

You will be asked to confirm your eligibility and provide contact information in this section. In addition to the applicant information requested above, you will be asked to upload the following documents:

Applicant's Biosketch in NIH Format

Limit 5 pages; should include any pending support and follow current NIH guidelines.

Abstract/Project Information

The information in this section is general information about the grant submission.

A. Project Title (limit 200 characters including spaces)

Make your title specific and detailed. It should clearly state the topic of your proposal.

B. Abstract (limit 2,000 characters including spaces)

Succinctly describe the hypothesis to be tested, the specific aims or global objectives of the project and the expected results.

C. Relevance to Foundation's Mission (limit 1,000 characters including spaces)

Briefly describe how your proposed project is relevant to the Foundation's mission to improve the health of people with rheumatic disease. In this section, be succinct and use plain language that can be understood by a lay audience. This information is made public for all awarded grants and used by the Foundation for marketing efforts.

D. Patient Impact (limit 1,500 characters including spaces)

In what ways will your Foundation funded award ultimately impact patients?

E. Keywords

Choose three keywords that accurately describe the project. If the application focuses on a specific disease, please include it as a keyword.

- F. The following questions will be used to assign your application to the appropriate reviewer. Please select one or more of the options in the online application.
 - Primary Research Material
 - Science Category
 - Primary Research Method/Area
 - Research Classification
 - Primary Biomedical/Health Research Category

Budget & Justification

Applications must include an itemized budget and justification indicating how the \$75,000 in direct costs associated with this award will be spent. The amount of the award can be divided between salary and fringe benefits and/or research costs (maximum of \$25,000 research costs). The total salary requested must be based on full-time, 12-month faculty appointment requiring the candidate to devote a minimum of 75% of the full-time professional effort to conducting research with the remaining effort being devoted to activities related to the development of a successful research career. Indirect costs are not allowed.

Current & Pending Support

Applicant should list all current and pending research support, including but not limited to grants and contracts. Indicate any current startup funds. For each entry specify the overlap between the other awards, applications, and/or sources listed in this application.

Organization Assurances

The applicant assures that the proposal is in compliance with institutional guidelines as provided by the sponsoring institution's clinical and research review boards. All research proposals including human subjects, laboratory animals and recombinant DNA techniques must show documented compliance with institutional guidelines. Copies of approval notices by the institutions IRB, IACUC and/or biosafety committees must be provided as appropriate once awarded.

Required Documents

Please upload the following:

NIH/VA Face Page

As submitted in original application.

NIH/VA Summary Sheets

Statement from Applicant

Four pages maximum. This item must be completed by the applicant and reviewed by the Primary Mentor. The statement should outline the applicant's strategy for a comprehensive response to the NIH/VA critique in a substantive and meaningful way that will result in re-submission during the period of bridge funding.

This should include:

- The one-page "Introduction to Application" that the applicant plans to submit with the K grant resubmission.
- Supporting information detailing: a) plans for acquiring specific preliminary data to be included in the K grant resubmission; b) additional training or career development to support the response; and c) timeline for the proposed work which should include grant resubmission (up to 3 pages total).

Letter of Institutional Support

The department chair must provide evidence of adequate institutional support and protected time to allow completion of the proposed work and submission of an application for independent research funding. The institution must agree to protect at least 75% of the applicant's time and effort for research. The amount of additional salary support from the institution should be stated. The letter should explicitly state how the institution will support the applicant through the process of competing for career development support.